Log in to search using one of your social media accounts:

This page shows you the latest news items in this category. This is page number 12.

B cells produce antibodies 'when danger calls, but not when it whispers,' scientists report
The immune system’s B cells protect us from disease by producing antibodies, or "smart bullets," that specifically target invaders such as pathogens and viruses while leaving harmless molecules alone. But how do B cells determine whether a threat is real and whether to start producing these weapons? An international team of life scientists shows in the May 16 issue of the journal Science how and why these cells respond only to true threats. "It is critical for B cells to respond either fully or not at all. Anything in between causes disease," said the study’s senior author, Alexander Hoffmann, a professor of microbio...
Source: UCLA Newsroom: Health Sciences - May 15, 2014 Category: Universities & Medical Training Source Type: news

Heart failure hospitalisation more than doubles in IBD flares
Dr Søren L. Kristensen, lead author, said: “Previous studies have shown an association between chronic inflammatory diseases (psoriasis, rheumatoid arthritis, systemic lupus erythematosus, celiac disease and IBD) and an increased incidence of venous- and arterial thrombotic disease (primarily heart attack and stroke). Researchers suggest the link is at least in part caused by inflammatory prothrombotic effects.” Topics: Heart Failure (HF) (Source: ESC News and Press)
Source: ESC News and Press - May 14, 2014 Category: Cardiology Source Type: news

Shingle Risk High in Lupus, RA, COPD
(MedPage Today) -- Patients with autoimmune diseases and certain other chronic conditions are at increased risk for herpes zoster, a U.K. case-control study found. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - May 14, 2014 Category: Geriatrics Source Type: news

Lupus Studies Point to Gut Microbes, EpigeneticsLupus Studies Point to Gut Microbes, Epigenetics
Intestinal 'microbiome' and epigenetic changes in gene expression might contribute to systemic lupus erythematosus and could offer new routes to therapy, new studies have suggested. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 13, 2014 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Dear Lupus, I want me back
My name is Lauren Johnson. I'm an associate producer at CNN, and I have systemic lupus erythematosus. (Source: CNN.com - Health)
Source: CNN.com - Health - May 12, 2014 Category: Consumer Health News Source Type: news

Arthritis, lupus and asthma data a shot in arm for AstraZeneca
AstraZeneca received a filli as 4 experimental drugs for rheumatoid arthritis, lupus and asthma showed promising results in mid-stage clinical trials. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 12, 2014 Category: Pharmaceuticals Source Type: news

Arthritis, lupus and asthma data a shot in arm for AstraZeneca
LONDON (Reuters) - AstraZeneca, fighting a $106 billion bid approach from Pfizer, received a fillip on Monday as four experimental drugs for rheumatoid arthritis, lupus and asthma showed promising results in mid-stage clinical trials. (Source: Reuters: Health)
Source: Reuters: Health - May 12, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Rheuminations: Drug-Induced Lupus, a Case Report
LIVERPOOL (MedPage Today) -- Despite more than 15 years of experience with biologic therapies in rheumatology, unwelcome surprises can still happen, as was shown in this case report. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 9, 2014 Category: Primary Care Source Type: news

Low Vitamin D Worsens Lupus Risks in Kids (CME/CE)
(MedPage Today) -- Children with lupus commonly are vitamin D deficient, which may contribute to their heightened inflammatory status and cardiovascular risk, researchers reported. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - May 8, 2014 Category: Pediatrics Source Type: news

Lupus (Systemic Lupus Erythematosus)
Title: Lupus (Systemic Lupus Erythematosus)Category: Diseases and ConditionsCreated: 8/20/2013 2:45:00 PMLast Editorial Review: 5/8/2014 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - May 8, 2014 Category: Rheumatology Source Type: news

Global Market for Drugs to Treat SLE to Reach $2.6 Billion In 2018;...
According to a new report from BCC Research, the global market for drugs to treat systemic lupus erythematosus (SLE), is expected to grow to $2.6 billion by 2018, with a five-year compound annual...(PRWeb April 28, 2014)Read the full story at http://www.prweb.com/releases/2014/04/prweb11801657.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 29, 2014 Category: Pharmaceuticals Source Type: news

How To Reverse Lupus Now Review | How To Get Rid Of Lupus With Matt...
How To Reverse Lupus Now, written by Matt Traverso, is a new program that teaches people how to get rid of lupus efficiently. The review of How To Reverse Lupus Now on the site HealthReviewCenter.com...(PRWeb April 26, 2014)Read the full story at http://www.prweb.com/releases/reverse-lupus-now/review/prweb11799949.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 27, 2014 Category: Pharmaceuticals Source Type: news

Pregnancy Risks Higher for Blacks With Lupus
(MedPage Today) -- African-American women with lupus are at increased risk for adverse pregnancy outcomes, even before they are diagnosed with the disease, a retrospective study found. (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - April 26, 2014 Category: OBGYN Source Type: news

B-Cell Targeting Has Benefit in Severe Lupus (CME/CE)
(MedPage Today) -- Although an inhibitor of B-cell activating factor failed to meet the primary endpoint in a phase II trial for lupus, beneficial effects were seen in patients with severe disease at baseline, researchers reported. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 24, 2014 Category: Primary Care Source Type: news

DC Residents Led by Nick Cannon in Walk to End Lupus Now
More than 4,000 people with lupus, their friends and families converged in the nation's capital on Saturday to shed light on the cruel mystery that is lupus. Grand marshaled by multi-talented entertainer and television personality Nick Cannon, the Lupus Foundation of America's Walk to End Lupus Now™ event in Washington, D.C. transformed Pennsylvania Avenue into a stream of purple, the color lupus advocates associate with this debilitating, poorly understood disease. (Source: Disabled World)
Source: Disabled World - April 20, 2014 Category: Disability Tags: Lupus Source Type: news

Treat-to-Target the New Goal in Lupus
(MedPage Today) -- An international task force has taken the first steps toward formulating a "treat to target" approach for the treatment of systemic lupus erythematosus (SLE), focusing on remission, damage prevention, and quality of life. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 18, 2014 Category: Primary Care Source Type: news

10 Common Mistakes in the Management of Lupus Nephritis10 Common Mistakes in the Management of Lupus Nephritis
Are the most common ways to treat lupus nephritis necessarily the most effective and the safest? This new study takes a look. American Journal of Kidney Diseases (Source: Medscape Nephrology Headlines)
Source: Medscape Nephrology Headlines - April 18, 2014 Category: Urology & Nephrology Tags: Nephrology Journal Article Source Type: news

Smoking Tied to Worse Lupus, Arthritis (CME/CE)
(MedPage Today) -- Worse patterns of disease for both rheumatoid arthritis and systemic lupus erythematosus were seen among patients who were smokers, and the risks actually increased after quitting for those with lupus, Swedish researchers reported. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 13, 2014 Category: Geriatrics Source Type: news

Stem Cells Seen as Promising in Lupus (CME/CE)
(MedPage Today) -- Mesenchymal stem cell transplantation is showing promise as a treatment for refractory systemic lupus erythematosus, researchers have reported. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 11, 2014 Category: Primary Care Source Type: news

In Vivo Cell Transfer Assay to Detect Autoreactive T Cell Subsets
Among the methods used in molecular biology, in vitro biochemical assays are more common, whereas in vivo assays, including the use of animal models, are less widely employed. In our studies on systemic lupus erythematosus (SLE), we have identified a novel T cell subtype termed “autoantibody-inducing CD4 T cells” (aiCD4 T cell) that is responsible for the development of autoimmunity. In order to identify and isolate these cells, we developed a new technique that involves the transfer of candidate T cell subpopulations into naïve mice and assaying for the development of autoantibodies in the recipient mice....
Source: Springer protocols feed by Molecular Medicine - April 7, 2014 Category: Molecular Biology Source Type: news

Induction of De Novo Autoimmune Disease in Normal Mice upon Repeated Immunization with Antigen
We describe here a novel and completely reproducible experimental technique that can induce systemic autoimmunity or systemic lupus erythematosus (SLE) in mice otherwise not prone to spontaneous autoimmune disease. This protocol involves the repeated immunization of mice with the same antigen. This rather simple technique enables us to perform exact and quantitative in vivo animal experiments with great accuracy. (Source: Springer protocols feed by Molecular Medicine)
Source: Springer protocols feed by Molecular Medicine - April 7, 2014 Category: Molecular Biology Source Type: news

What is Lupus: Mayo Clinic Radio Health Minute
In this Mayo Clinic Radio Health Minute, Dr. Vaidehi Chowdhary explain lupus. To listen, click the link below. What is Lupus   (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 2, 2014 Category: Databases & Libraries Source Type: news

Shingles Vaccine OK in Mild Lupus
NEW YORK (MedPage Today) -- Vaccination against shingles may be safe for patients with mild, stable systemic lupus erythematosus, a researcher said here. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 24, 2014 Category: Geriatrics Source Type: news

Primary Cardiac Disease Still Occurs in Lupus
(MedPage Today) -- Pericarditis and other forms of primary cardiac disease can occur at any time during the course of systemic lupus erythematosus, but antimalarial treatment can be protective, South American researchers reported. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 19, 2014 Category: Primary Care Source Type: news

Discounted Systemic Lupus Erythematosus and Lupus Nephritis Treatment...
Discounted research study “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022” elaborated by GlobalData is now available at...(PRWeb March 18, 2014)Read the full story at http://www.prweb.com/releases/2014/03/prweb11679578.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 18, 2014 Category: Pharmaceuticals Source Type: news

Class, ancestry and medication are factors in cardiac risk for lupus patients
New research published in Rheumatology, the international, peer-reviewed scientific journal, has suggested that systemic lupus erythematosus (SLE) patients of African descent and from lower socioeconomic groups face a higher risk of primary cardiac disease. However, those taking anti-malarial drugs reduce their risk.The research found that 14% of patients experience cardiac problems as a result of the auto-immune disorder within five years of diagnosis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 18, 2014 Category: Consumer Health News Tags: Lupus Source Type: news

What are expectations that can come from the Accelerating Medicines Partnership?
Virginia Ladd - AMP Submitted by Julie on Mon, 03/17/2014 - 12:45 Autoimmune diseases affect 50 million Americans and are a leading cause of death and disability — yet we have no cure. Historically, the first goal of treatment is to reduce inflammation focusing on making quality of life as good as possible. However, more needs to be done on greater research options for all autoimmune disease-related patients. Share Email Print var switchTo5x = false;var __st_loadLate = true;stLight.options({"publisher":"dr-e0d16a36-b72f-d979-d8a1-314a351971a6...
Source: PHRMA - March 17, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

Leslie Hanrahan - AMP
We believe this initiative will ultimately lead to new understanding of the underlying causes of lupus along with new therapies for this disease and ultimately an improved quality of life for people living with lupus. For us it is all about the patient! Lupus is  complex and is arguably the most clinically diverse of all autoimmune diseases. Because of this, the scope of the Accelerating Medicines Partnership (AMP)  is tailor made for a collaborative effort among the NIH, industry, academic medical research centers and non profit organization. Lupus was selected for this project because of the lack of effective targeted ...
Source: PHRMA - March 17, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

Gary Nabel - AMP
It has been said that all boats rise with the tide. That’s the analogy that comes to mind when thinking about the potential of the Accelerating Medicines Partnership (AMP). By bringing together stakeholders from the National Institutes of Health (NIH), biopharmaceutical companies and several non-profit organizations, AMP is a great opportunity for all of us to join together and develop a broad-based understanding about some of the chronic conditions facing patients today. Sanofi is excited to be participating in two of the AMP focus areas: type 2 diabetes and rheumatoid arthritis/lupus. It may seem counterintuitive for 1...
Source: PHRMA - March 17, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

Virginia Ladd - AMP
Autoimmune diseases affect 50 million Americans and are a leading cause of death and disability — yet we have no cure. Historically, the first goal of treatment is to reduce inflammation focusing on making quality of life as good as possible. However, more needs to be done on greater research options for all autoimmune disease-related patients. In existing research, 80-100 different autoimmune diseases have been identified and researchers suspect at least 40 additional diseases of having an autoimmune basis. These diseases are chronic and can be life-threatening. The American Autoimmune Related Diseases Association (AARD...
Source: PHRMA - March 17, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

HIV vaccine hope found in immune system of a unique patient
The Journal of Clinical Investigation has published a new study of a unique patient with an immune system that produces the types of neutralizing antibodies that are considered essential to an effective HIV vaccine response.The patient has a rare combination of HIV and systemic lupus erythematosus or SLE, a disease where the immune system attacks the body's own cells and tissue.Senior author Barton F. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 14, 2014 Category: Consumer Health News Tags: HIV / AIDS Source Type: news

New Antibody Shows Promise in Lupus
(MedPage Today) -- Initial clinical studies of epratuzumab in patients with active, moderate-to-severe systemic lupus erythematosus are suggesting promise for this monoclonal antibody. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 12, 2014 Category: Primary Care Source Type: news

Vaccine hope for HIV offered by unique individual's immune response to virus
One person's unique ability to fight HIV has provided key insights into an immune response that researchers now hope to trigger with a vaccine, according to findings reported by a team that includes Duke Medicine scientists.The person had a rare combination of both lupus and HIV. Lupus, specifically systemic lupus erythematosus, or SLE, is a disease in which the immune system attacks the body's cells and tissue. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 12, 2014 Category: Consumer Health News Tags: Immune System / Vaccines Source Type: news

Paid Lupus Clinical Trial Now Enrolling at Achieve Clinical Research...
Achieve is conducting a phase II, placebo-controlled, multi dose, 24-week clinical study to evaluate the efficacy and safety of a new autoimmune medication in participants living with...(PRWeb March 11, 2014)Read the full story at http://www.prweb.com/releases/2014/03/prweb11643043.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 11, 2014 Category: Pharmaceuticals Source Type: news

Jury Awards Lupus Sufferer $800,000 For Insurer's Bad Faith Coverage Denial
SAN FRANCISCO - After an eight-day trial, a California federal jury on Feb. 13 found that an insurer breached its contract and acted in bad faith by denying long-term disability (LTD) coverage to a woman diagnosed with lupus, awarding her more than $873,622 in unpaid benefits and compensatory damages (Cassaundra Ellena v. Standard Insurance Co., et al., No. 3:12-cv-05401, N.D. Calif.). (Source: LexisNexis® Mealey's™ Disability Insurance Legal News)
Source: LexisNexis® Mealey's™ Disability Insurance Legal News - March 11, 2014 Category: Medical Law Source Type: news

Unique individual with lupus and HIV demonstrates desired immune response to HIV
One person’s unique ability to fight HIV has provided key insights into an immune response that researchers now hope to trigger with a vaccine, according to new findings. The person had a rare combination of both lupus and HIV. Lupus, specifically systemic lupus erythematosus, or SLE, is a disease in which the immune system attacks the body's cells and tissue. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 10, 2014 Category: Science Source Type: news

JCI online ahead of print table of contents for March 10, 2014
(Journal of Clinical Investigation) This release contains summaries, links to PDFs, and contact information for the following newsworthy papers published online, March 10, 2014 in the JCI: 'Identification of a broadly neutralizing HIV-1 antibody in a lupus patient,' 'Evaluating disease-associated protein turnover kinetics,' 'Transport properties of pancreatic cancer describe gemcitabine delivery and response,' 'HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers,' 'iNKT cells require TSC1 for terminal maturation and effector lineage fate decisions,' and more. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 10, 2014 Category: Global & Universal Source Type: news

Medical Marijuana not Recommended for Rheumatoid Arthritis, Lupus, or Fibromyalgia Symptoms
Patients with rheumatic conditions are in need of symptom relief and some are turning to herbal cannabis as a treatment option. However, the effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence. A new article published in Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), explores the risks associated with using herbal cannabis for medicinal purposes and advises healthcare providers to discourage rheumatology patients from using this drug as therapy. (Source: Disabled World)
Source: Disabled World - March 9, 2014 Category: Disability Tags: Medical Marijuana Source Type: news

Researchers discourage rheumatology patients from using cannabis
Patients with rheumatic conditions are in need of symptom relief and some are turning to herbal cannabis as a treatment option. However, the effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 6, 2014 Category: Consumer Health News Tags: Arthritis / Rheumatology Source Type: news

Leslie Hanrahan
Vice President, Education and Research of the Lupus Foundation of America, Inc.Leslie Hanrahan has over 22 years’ experience in health communications, education and research programming. Since 2005, Ms. Hanrahan has led the strategic development and growth of the Education and Research Department of the Lupus Foundation of America (LFA).  The Lupus Foundation of America is the only national force devoted to solving the mystery of lupus, one of the world’s cruelest, most unpredictable and devastating diseases, while giving caring support to those who suffer from its brutal impact.  Prior to joining the LFA, Ms. Hanrah...
Source: PHRMA - March 5, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news

How Wolves Change Rivers | video | @GrrlScientist
Wolves are top predators that have far-reaching beneficial effects upon entire ecosystems -- including the structure of rivers.Wolves are crucial for maintaining a healthy ecosystem -- a fact that was conveniently forgotten when they were exterminated from almost all of the continental United States by ranchers, farmers, trappers and hunters.Meanwhile, the populations of other animals exploded. The entire ecosystem of the American wilderness was changed by exploding populations of large ungulates -- particularly wapiti, Cervus canadensis. (These animals are more commonly known as "elk" -- note that the narrator in the acco...
Source: Guardian Unlimited Science - March 3, 2014 Category: Science Authors: GrrlScientist Tags: theguardian.com Blogposts Biology National parks Animals Plants Zoology Environment Science Source Type: news

Herbal cannabis not recommended for rheumatology patients
Patients with rheumatic conditions are in need of symptom relief and some are turning to herbal cannabis as a treatment option. However, the effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence. A new article explores the risks associated with using herbal cannabis for medicinal purposes and advises healthcare providers to discourage rheumatology patients from using this drug as therapy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 3, 2014 Category: Science Source Type: news

What are some realistic expectations that can come from the Accelerating Medicines Partnership?
Opinionconversations48254827Autoimmune diseases affect 50 million Americans and are a leading cause of death and disability — yet we have no cure. Historically, the first goal of treatment is to reduce inflammation focusing on making quality of life as good as possible. However, more needs to be done on greater research options for all autoimmune disease-related patients. In existing research, 80-100 different autoimmune diseases have been identified and researchers suspect at least 40 additional diseases of having an autoimmune basis. These diseases are chronic and can be life-threatening. The American Autoimmune Relate...
Source: PHRMA - February 26, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

Virginia T. Ladd
President & Executive Director, American Autoimmune Related Diseases Association, Inc. Virginia T. Ladd, R.T. – Virginia Ladd is the President and Executive Director of the American Autoimmune Related Diseases Association, Inc. (AARDA), an organization that she founded to bring a national focus to autoimmunity and increase collaboration in autoimmune research, education, awareness, and advocacy. She has been involved in the nonprofit community for over 30 years as a patient advocate and educator. Mrs. Ladd served as president and executive director of the Lupus Foundation of America. Mrs. Ladd was instrumental in the...
Source: PHRMA - February 26, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

What are our greatest challenges as we address managing chronic diseases like diabetes?
conversationsphrmapediaOpinion480448091404Despite many attempts by prominent researchers utilizing different approaches, there is no cure for diabetes. While continuing extensive research looking into “the cure”, much work is being conducted in the day –to- day management of diabetes. As such, it is essential to develop treatments that not only help measure and adjust blood glucose levels- thus preventing hyper and hypoglycemia, but also to improve the quality of life in our patients with diabetes. The amount of self care skills required to manage diabetes is extensive, requiring blood glucose monitoring, insulin inj...
Source: PHRMA - February 11, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

Progression From Cutaneous to Systemic Lupus Erythematosus Progression From Cutaneous to Systemic Lupus Erythematosus
Most patients who progress from cutaneous lupus erythematosus (CLE) to systemic lupus erythematosus (SLE) do not develop significant systemic manifestations, according to a longitudinal study. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 7, 2014 Category: Dermatology Tags: Dermatology News Source Type: news

Measuring Interferon Alpha and Other Cytokines in SLE
We describe a functional assay to measure type I IFN activity in SLE plasma and have also measured the response of peripheral blood cells to that cytokine family. This method can be scaled to assess IFN functional activity, as well as activity and cellular response to other cytokines, in relation to cellular and serologic parameters relevant to SLE. (Source: Springer protocols feed by Immunology)
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Induced Murine Models of Systemic Lupus Erythematosus
Induced mouse models of systemic lupus erythematosus (SLE) have been developed to complement the spontaneous models. This chapter describes the methods used in the pristane-induced model and the chronic graft-versus-host disease (cGVHD) model, both of which have been extensively used. We will also outline the specific mechanisms of systemic autoimmunity that can be best characterized using each of these models. (Source: Springer protocols feed by Immunology)
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

TLC Immunostaining for Detection of “Antiphospholipid” Antibodies
Thin-layer chromatography (TLC) is a nonquantitative technique, which has been employed in the detection of antiphospholipid (aPL) antibodies. Antiphospholipid syndrome (APS) is the most frequently acquired thrombophilia, characterized by thrombosis and obstetric manifestations associated to an autoimmune trait, represented by the positivity of antiphospholipid (aPL) antibodies. Immunoassays for anticardiolipin (aCL) and anti-β2 glycoprotein I (aβ2GPI) antibodies and clotting tests for lupus anticoagulant (LA) represent the standard tests for the routine detection of aPL. The term “seronegative APS” h...
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news

Bifunctional Antibody Fragment-Based Fusion Proteins for the Targeted Elimination of Pathogenic T-Cell Subsets
Pathogenic effector T cells are key contributors to autoimmune diseases such as systemic lupus erythematosus (SLE). General inhibition of T cells using, e.g., methotrexate, prednisolone, or TNF blockers, has prominent therapeutic effects frequently at the cost of severe long-term side effects and toxicity. Therefore, targeted strategies that can selectively inhibit or eliminate pathogenic T cells are sought after as a new approach to safely block perpetual inflammatory T-cell responses and inhibit concomitant progressive tissue destruction. Of particular interest in this respect is the use of the so-called single-chain fra...
Source: Springer protocols feed by Immunology - February 7, 2014 Category: Allergy & Immunology Source Type: news